Your browser doesn't support javascript.
loading
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes, Jorge E; Gambacorti-Passerini, Carlo; Deininger, Michael W; Mauro, Michael J; Chuah, Charles; Kim, Dong-Wook; Dyagil, Irina; Glushko, Nataliia; Milojkovic, Dragana; le Coutre, Philipp; Garcia-Gutierrez, Valentin; Reilly, Laurence; Jeynes-Ellis, Allison; Leip, Eric; Bardy-Bouxin, Nathalie; Hochhaus, Andreas; Brümmendorf, Tim H.
Afiliação
  • Cortes JE; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Gambacorti-Passerini C; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Deininger MW; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Mauro MJ; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Chuah C; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Kim DW; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Dyagil I; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Glushko N; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Milojkovic D; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • le Coutre P; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Garcia-Gutierrez V; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Reilly L; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Jeynes-Ellis A; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Leip E; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Bardy-Bouxin N; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Hochhaus A; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
  • Brümmendorf TH; Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Si
J Clin Oncol ; 36(3): 231-237, 2018 01 20.
Article em En | MEDLINE | ID: mdl-29091516
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinolinas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Inibidores de Proteínas Quinases / Mesilato de Imatinib / Compostos de Anilina / Antineoplásicos / Nitrilas Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Eslovênia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinolinas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Inibidores de Proteínas Quinases / Mesilato de Imatinib / Compostos de Anilina / Antineoplásicos / Nitrilas Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Eslovênia